

RESEARCH ARTICLE

The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts

Veerle van Gils¹  | Willemijn J. Jansen¹ | Wiesje M. van der Flier^{2,3} | Pablo Martinez-Lage⁴ | Jakub Hort⁵ | Inez H. G. B. Ramakers¹ | Olivier Rouaud⁶ | Markku Laakso⁷ | Sebastiaan Engelborghs^{8,9} | Julius Popp^{10,11} | Alberto Lleó^{12,13} | Anders Wallin¹⁴ | Magda Tsolaki¹⁵ | Charlotte E. Teunissen¹⁶ | Rik Vandenberghe^{17,18} | Yvonne Freund-Levi¹⁹ | Lutz Frölich²⁰ | Henrik Zetterberg^{21,22,23,24} | Johannes Streffer^{25,26} | Simon Lovestone²⁷ | Justine Moonen^{2,3} | Argonde van Harten^{2,3} | Katerina Veverová⁵ | Nienke Legdeur^{2,3} | Anouk den Braber^{2,3,28} | Daniel Damian⁶ | Anette Hall^{7,19} | Janita Bralten^{29,30} | Giuseppe Fanelli^{29,30,31} | Barbara Franke^{29,30} | Geert Poelmans²⁹ | Monica Bulló^{32,33,34} | Susana Jimenez-Murcia^{35,36,37,38} | Fernando Fernandez-Aranda^{35,36,37,38} | Jordi Salas-Salvadó^{33,37,39} | Søren Dalsgaard^{40,41} | Pieter Jelle Visser^{1,2} | Stephanie J. B. Vos¹

Correspondence

Dr. Veerle van Gils, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands.
Email: vvangils@maastrichtuniversity.nl

Funding information

European Community's Horizon H2020/2014 - 2020, Grant/Award Number: 847879; EU/EFPIA Innovative Medicines Initiative Joint Undertaking, Grant/Award Number: 115736; Alzheimer's Association, Grant/Award Number: SG21-818099-EPAD; Marie Curie International Training Network, Grant/Award Number: 860197; Innovative Medicines Initiatives, Grant/Award Numbers: 831434, 101034344; National MS Society; Alzheimer's Drug Discovery Foundation; Health Holland; Dutch Research Council; The Selfridges Group Foundation; ZonMw, Grant/Award Numbers: #73305095007, #10510032120003; Topsector Life Sciences & Health, Grant/Award Number: #LSHM20106; Dutch National Dementia Strategy; Swedish Research Council, Grant/Award Numbers: #2023-00356, #2022-01018, #2019-02397;

Abstract

INTRODUCTION: It remains unclear whether diabetes mellitus (DM) is associated with Alzheimer's disease (AD) pathology and associated vascular burden.

METHODS: We included cognitively normal (CN), mild cognitive impairment (MCI), and dementia individuals. We assessed associations between DM and AD biomarkers (amyloid beta [A β], phosphorylated tau-181 [p-tau181], total tau [t-tau], and medial temporal atrophy [MTA]) and vascular burden (white matter hyperintensities, microbleeds) by logistic regression. Secondary analyses assessed associations between DM and profiles of A β combined with p-tau181/t-tau/MTA/white matter hyperintensity/microbleeds.

RESULTS: We included 5550 participants (65.8 $\pm$ 8.7 years, 8.7% DM). DM was associated with lower odds of abnormal AD biomarkers: A β in MCI (odds ratio [OR] = 0.70, 95% confidence interval [CI]: 0.51–0.95, p = 0.02) and dementia (OR = 0.44, 0.26–0.78, p = 0.003), and p-tau181 in dementia (OR = 0.64, 0.41–1.00, p = 0.045). Secondary analyses indicated associations of DM with abnormal t-tau (OR = 1.57, 1.00–2.46, p = 0.048) and MTA (OR = 1.96, 1.05–3.68, p = 0.04) only in CN individuals with normal A β .

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

European Union's Horizon Europe research and innovation programme, Grant/Award Number: 101053962; Swedish State Support for Clinical Research, Grant/Award Numbers: #201809-2016862, #ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, #ADSF-24-1284328-C; Bluefield Project; Cure Alzheimer's Fund; Olav Thon Foundation; the Erling-Persson Family Foundation; Familjen Rönströms Stiftelse; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden, Grant/Award Number: #FO2022-0270; Marie Skłodowska-Curie, Grant/Award Number: 860197; Union Joint Programme – Neurodegenerative Disease Research, Grant/Award Number: JPN2021-00694; National Institute for Health; Care Research University College London Hospitals Biomedical Research Centre; UK Dementia Research Institute, Grant/Award Number: UKDRI-1003; Autonomous Government of Catalonia

DISCUSSION: In cognitively impaired individuals, DM was associated with lower odds of A β pathology, whereas DM was associated with neurodegeneration markers in CN individuals without A β pathology.

KEYWORDS

diabetes mellitus, medial temporal atrophy (MTA), microbleeds, tau, amyloid beta, cerebrospinal fluid (CSF), elderly persons, magnetic resonance imaging (MRI), positron emission tomography (PET), white matter hyperintensity (WMH)

Highlights

- Diabetes mellitus (DM) was associated with lower odds of amyloid beta (A β) and phosphorylated tau (p-tau) pathology across clinical populations.
- DM was associated with total tau and medial temporal atrophy in cognitively normal individuals without A β pathology.
- DM may be associated with dementia through neurodegenerative pathways other than Alzheimer's disease.

1 | BACKGROUND

Alzheimer's disease (AD) constitutes the majority of dementia cases and increases steadily in prevalence across Europe.¹ AD often co-occurs with cardiovascular and metabolic diseases, such as diabetes mellitus (DM). Many studies have indicated associations of DM, hyperglycemia, and insulin resistance with worse cognitive performance and cognitive decline,^{2,3} and increased risk of developing AD dementia.⁴ Moreover, it has been suggested that AD and DM share similar mechanisms of insulin resistance, and patterns of vascular burden and atrophy, in the brain.^{5–7} Nevertheless, the relationship between DM and AD pathology and associated vascular burden remains unclear. This knowledge is particularly important for understanding the etiology underlying AD.

AD is typically characterized by amyloid beta (A β) and tau pathology, which can be measured through biomarkers.⁸ Commonly used biomarkers include A β 42 in cerebrospinal fluid (CSF) or global A β on positron emission tomography (PET), and phosphorylated tau (p-tau) in CSF. Neurodegeneration markers less specific to AD include CSF total tau (t-tau) and medial temporal atrophy (MTA). Commonly observed vascular co-pathologies with AD are white matter hyperintensities (WMHs) and microbleeds, which are detectable with magnetic resonance imaging (MRI).

Few studies have assessed the relationship between DM and specific AD biomarkers, and results have been inconclusive.^{6,9,10} These inconsistencies may be due to differences in study populations, cognitive status, and definitions of DM. Associations of DM with brain atrophy and vascular burden, such as WMHs, have been shown repeatedly in population studies.^{6,11,12} However, it remains unclear if these changes are also observed in aging and memory clinic settings and whether these pathologies reflect changes related to AD.

Our study aimed to assess whether DM is associated with (1) AD-related biomarkers (i.e., A β , p-tau181, t-tau, and MTA), and (2) markers of vascular burden on MRI (i.e., WMHs and microbleeds) in memory clinic and aging cohorts, including participants across the AD clinical spectrum, that is, cognitively normal (CN), mild cognitive impairment (MCI), and dementia. As secondary analysis, we explored the association of DM with biomarker profiles based on A β abnormality in combination with the presence of tau, MTA, or vascular burden to assess whether DM is differently associated with pathologies across stages of AD based on amyloid status.

2 | METHODS

2.1 | Participants

We performed this study as part of the Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME) project, exploring the role of insulin signaling in brain disorders. We included 5550 participants from 10 existing aging and memory clinic cohorts in Europe: Amsterdam Dementia Cohort (ADC, $n = 2,286$),¹³ BioBank Alzheimer Center Limburg (BB-ACL, $n = 156$),¹⁴ European Medical Information Framework (EMIF) PreclinAD ($n = 199$)¹⁵ and EMIF 90+ ($n = 100$)¹⁶ in The Netherlands, Czech Brain Aging Study (CBAS, $n = 227$) in the Czech Republic,¹⁷ Gipuzkoa Alzheimer Project (GAP, $n = 192$) in Spain,¹⁸ CLEMENS ($n = 185$) in Switzerland,¹⁹ Metabolic Syndrome in Men (METSIM, $n = 58$) in Finland,²⁰ and the European multi-cohort studies European Medical Information Framework (EMIF) Multimodal Biomarker Discovery Study (MBD, $n = 381$)²¹ and European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS, $n = 1766$).²² Overlapping participants across cohorts were

RESEARCH IN CONTEXT

- 1. Systematic review:** Many studies have demonstrated an association between diabetes mellitus (DM) and a clinical diagnosis of Alzheimer's disease (AD) dementia. To date, it remains largely unclear whether DM is also associated with underlying AD biomarkers.
- 2. Interpretation:** Our study showed that DM is consistently associated with lower odds of amyloid- β in individuals with dementia, whereas DM was associated with neurodegeneration markers in cognitively normal individuals with normal amyloid- β . These findings suggest that DM may be associated with cognitive decline through processes of neurodegeneration different from amyloid- β pathways.
- 3. Future directions:** For improving diagnostic and prognostic procedures, further research exploring the underlying mechanisms behind the associations between DM, neurodegeneration, and cognitive decline is necessary.

excluded. Further details on inclusion and definitions across cohorts are provided in Table S1.

Participants were included if data were available on DM diagnosis or use of antidiabetics from which a DM diagnosis could be inferred. In addition, at least one AD biomarker measure of A β or tau had to be available, that is, CSF A β 42, amyloid-PET, CSF p-tau181, or t-tau. No additional inclusion or exclusion criteria were considered.

All cohort studies were approved by the local ethics committees and conducted according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants gave written informed consent at their respective sites. As only existing data were used, this study was not subject to approval by the medical ethical committee (METC) at the Maastricht University Medical Center (MUMC+), declaration number 2020-2481. The research project was approved by the MUMC+ Board of Directors.

2.2 | Clinical assessment

All participants were assessed through standard protocol procedures at each site, including neurological and psychiatric assessment, medical history, and neuropsychological examination. The presence of DM was indicated by medical history or self-report ($n = 5524$), or by DM medication use (i.e., insulin or oral glucose lowering drugs; $n = 5086$). The used definitions for each cohort are described in S1. Although we could not differentiate for diabetes type (i.e., type 1 or 2), the sample primarily reflects type 2 DM, as this constitutes the majority of cases, especially at an older age.²³ The presence of cardiometabolic comorbidities (i.e., obesity, hypertension, hypercholesterolemia) was based on medical history.

Cognitive status was established in each cohort according to standard study protocols. Definitions per cohort are described in Table S1. Overall, individuals were classified as MCI if showing impairment on neuropsychological tests^{24–26} and/or the Clinical Dementia Rating scale (CDR = 0.5).²⁷ In each cohort, a clinical diagnosis of dementia was defined by either the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRA),²⁸ European Federation of Neurological Societies-European Neurological Society (EFNS-ENS),²⁹ or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria diagnosed by a professional. Across all cohorts, most or all dementia cases concerned AD dementia. Individuals with neuropsychological scores within the normal range, and thus not classified as MCI or dementia, were classified as CN.

2.3 | Assessment of AD biomarkers and vascular burden

2.3.1 | CSF measures

Nine cohorts (all except EMIF 90+) determined A β 42 ($n = 5205$), p-tau181 ($n = 5204$), and t-tau ($n = 5191$) levels from CSF using lumbar puncture. For Innotech enzyme-linked immunosorbent assays (ELISAs), we used cutoffs calculated by Gaussian mixture modeling to define A β abnormality, as these cutoffs are shown to better capture abnormal levels of A β over time.^{30,31} For other A β assays, cutoffs were locally defined per cohort.^{30,32} We used predefined and local p-tau181 and t-tau cutoffs for all cohorts. Data availability for biomarkers per cohort are reported in Table S2. Biomarker modality, cutoffs, and assays are further specified in Table S3.

2.3.2 | PET measures

Three cohorts measured A β by both PET scans and CSF (ADC, CBAS, and EMIF PreclinAD). One cohort (EMIF 90+) measured A β on PET only. A β abnormality was assessed through visual assessment according to local study protocols. We used PET measures if CSF measures were unavailable or unreliable ($n = 342$). The modality and tracers are specified in Table S3.

2.3.3 | MRI measures

MRI measures were available in eight cohorts (ADC, BB-ACL, CBAS, GAP, EMIF MBD, EMIF Preclin-AD, EMIF 90+, and EPAD). We used 1.5T or 3T MRI scanners and validated semi-qualitative visual rating scales to assess MTA and WMHs in all eight cohorts. The Scheltens scale was used to define MTA severity, with a score ranging from 0–4³³ and is based on three brain structures: the choroid fissure, temporal horn of the lateral ventricle, and hippocampus. The Fazekas scale was used to measure severity of WMHs, with a score

ranging from 0–3.³⁴ The total count of microbleeds was determined in seven cohorts (abovementioned minus GAP, $n = 4127$). The presence of MTA and WMHs was defined by scores ≥ 2 .^{35,36} The presence of microbleeds was defined by having at least 1 (≥ 1) microbleed. Details on the availability of MRI measures per cohort are described in Table S2.

2.4 | APOE $\epsilon 4$ carriership

For nine cohorts (all except CLEMENS), data on apolipoprotein E $\epsilon 4$ (APOE $\epsilon 4$) carriership was available for most participants ($n = 5150$). APOE $\epsilon 4$ carriership was defined by carrying at least one $\epsilon 4$ allele (yes/no). Details on the availability of APOE $\epsilon 4$ carriership per cohort are described in S2.

2.5 | Profiles of A β with other AD and vascular burden markers

For secondary analyses, we classified participants into different biomarker profiles based on A β abnormality in combination with abnormality of one other AD biomarker (p-tau181, t-tau, or MTA) or vascular burden marker (WMHs or microbleeds), with a plus (+) indicating abnormal biomarker levels, and a minus (–) indicating normal biomarker levels.

2.6 | Statistical analyses

Pearson chi-square test and one-way analysis of variance (ANOVA) were used to compare baseline characteristics between cognitive status groups (i.e., CN, MCI, and dementia). As main analyses, separate logistic regression models were used to assess the associations between DM as predictor and dichotomized (normal/abnormal) AD biomarkers (A β , p-tau181, t-tau, and MTA) or vascular burden (WMHs and microbleeds) as outcome measures. Analyses were stratified for cognitive status, and all models were adjusted for age, sex, and cohort. In additional models, we added APOE $\epsilon 4$ carriership and common vascular comorbidities (obesity, hypertension, and hypercholesterolemia) as covariates. For secondary analyses, we used multinomial regression to explore the association of DM with profiles of A β combined with p-tau181, t-tau, MTA, WMHs, or microbleeds, to explore whether DM was differently associated with other AD or vascular biomarkers in the absence or presence of A β (indicating a more advanced AD stage). Reference categories were defined by normal A β (A) as well as by normal levels of the other AD or vascular biomarkers. Differences between the other subgroups were also tested.

In sensitivity analyses, we repeated the A β analyses in cohorts with only CSF measures (excluding EMIF 90+ with only PET measures) and assessed the effect of DM medication use through stratifying for medication use. In addition, we repeated all main analyses with DM x cohort interactions to explore differences in associations per

cohort. All analyses were performed using R, version 4.3.2 (2023), with significance levels set at $p < 0.05$. p -values after false discovery rate (FDR) corrections for multiple testing are additionally reported for all analyses.

3 | RESULTS

3.1 | Demographics

We included 5550 participants (49% women) with a mean age of 65.8 (SD = 8.7) years. Overall, 2686 individuals (48%) were classified as CN, 1524 (27%) individuals as MCI, and 1340 (24%) individuals were diagnosed with dementia. Participant characteristics stratified for cognitive status are described in Table 1. APOE $\epsilon 4$ carriership and AD biomarker abnormality differed between all cognitive groups (CN < MCI < dementia; all p 's < 0.001). Vascular burden was more prevalent in MCI as compared to CN (WMH: $p < 0.001$, microbleeds: $p = 0.004$). In total, 541 participants (8.7%) were diagnosed with DM, with the highest prevalence in the MCI group (13%) as compared to the CN (7.8%) and dementia (10%) groups. Notably, individuals with dementia had cardiometabolic comorbidities less often than the MCI group (obesity: $p = 0.02$, hypertension: $p < 0.001$, hypercholesterolemia: $p < 0.001$). Patient characteristics stratified by DM status are described in Table S4 and characteristics stratified by cohort are listed in Table S5.

Among CN individuals, 61% had both normal amyloid and p-tau markers, 19% had only abnormal amyloid, 12% had only abnormal p-tau, and 8% had both abnormal amyloid and p-tau. In the MCI group, 30% had both normal amyloid and p-tau markers, 25% had only abnormal amyloid, 12% had only abnormal p-tau, and 33% had both abnormal amyloid and p-tau. In the dementia group, 4% had both normal amyloid and p-tau markers, 17% had only abnormal amyloid, 3% had only abnormal p-tau, and 76% had both abnormal amyloid and p-tau. Overall, p-tau and t-tau were overlapping in 92% of the cases (55% with normal p-tau and t-tau, 37% with abnormal p-tau and t-tau).

3.2 | Associations of DM with AD biomarkers and vascular burden

Results on the associations of DM with AD biomarkers and MRI vascular burden are shown in Table 2 and Figure 1. In the CN group, no associations between DM and AD biomarkers or vascular burden markers were found. In the MCI and dementia groups, we found that individuals with DM had lower odds of abnormal A β as compared to normal A β (odds ratio [OR] = 0.70, $p = 0.02$ and OR = 0.44, $p = 0.003$, respectively). In the dementia group, individuals with DM also had lower odds of abnormal p-tau181 as compared to normal levels of p-tau181 (OR = 0.64, $p = 0.045$). No associations were found between DM and t-tau, MTA, WMHs, or microbleeds in the MCI and dementia groups. The odds distributions for each association are visualized in Figure S1.

TABLE 1 Participant characteristics stratified by cognitive status.

Variables	N	CN N = 2686	MCI N = 1524	Dementia N = 1340
Age, years, mean (SD)	5550	64.3 (8.9) ^{b,c}	67.8 (8.2) ^{a,c}	66.5 (8.3) ^{a,b}
Education, years, mean (SD)	5512	13.9 (3.9) ^{b,c}	12.5 (3.8) ^{a,c}	11.1 (3.5) ^{a,b}
Female, n (%)	5550	1,361 (51%) ^b	677 (44%) ^{a,c}	709 (53%) ^b
MMSE score, mean (SD)	5467	28.6 (1.5) ^{b,c}	26.7 (2.6) ^{a,c}	20.6 (5.1) ^{a,b}
APOE ε4 carrier, n (%)	5150	934 (36%) ^{b,c}	651 (50%) ^{a,c}	805 (65%) ^{a,b}
Abnormal CSF/PET Aβ, n (%)	5547	724 (27%) ^{b,c}	869 (57%) ^{a,c}	1,237 (92%) ^{a,b}
Abnormal CSF p-tau, n (%)	5204	490 (20%) ^{b,c}	657 (45%) ^{a,c}	1,006 (79%) ^{a,b}
Abnormal CSF t-tau, n (%)	5191	403 (16%) ^{b,c}	680 (47%) ^{a,c}	1,029 (81%) ^{a,b}
Abnormal MTA, n (%)	4368	258 (11%) ^{b,c}	299 (27%) ^{a,c}	402 (47%) ^{a,b}
Abnormal WMH, n (%)	4,484	381 (16%) ^{b,c}	318 (27%) ^a	226 (25%) ^a
Microbleeds, n (%)	4,127	361 (16%) ^{b,c}	225 (21%) ^a	182 (22%) ^a
DM, n (%)	5,550	209 (7.8%) ^{b,c}	195 (13%) ^{a,c}	137 (10%) ^{a,b}
Diabetes medication, n (%)	5086	161 (6.9%) ^b	170 (12%) ^{a,c}	110 (8.3%) ^b
Obesity, n (%)	5186	430 (17%) ^{b,c}	161 (12%) ^{a,c}	116 (9.2%) ^{a,b}
Hypertension, n (%)	5502	766 (29%) ^b	539 (36%) ^{a,c}	366 (28%) ^b
Hypercholesterolemia, n (%)	5457	653 (25%) ^c	406 (27%) ^c	187 (14%) ^{a,b}

Note: Abnormal Aβ was defined by either CSF or PET, depending on each cohort.

Abbreviations: ANOVA, analysis of variance; APOE, apolipoprotein E; CN, cognitively normal; CSF, cerebrospinal fluid; DM, diabetes mellitus; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MTA, medial temporal atrophy; p-tau, phosphorylated tau; PET, positron emission tomography; t-tau, total tau; WMH, white matter hyperintensity.

ANOVA indicated that CN, MCI, and dementia groups differed significantly on all variables (all *p*'s < 0.001). Post hoc analysis assessed group differences:

^aSignificantly different from CN.

^bSignificantly different from MCI.

^cSignificantly different from dementia.

TABLE 2 Associations of DM with AD biomarkers and vascular burden.

AD	CN			MCI			Dementia		
	OR (CI)	<i>p</i>	<i>p</i> FDR	OR (CI)	<i>p</i>	<i>p</i> FDR	OR (CI)	<i>p</i>	<i>p</i> FDR
Aβ	0.77 0.54 – 1.08	0.135	0.248	0.70 0.51 – 0.95	0.023	0.138	0.44 0.26 – 0.78	0.003	0.018
p-tau	1.27 0.87 – 1.84	0.207	0.248	0.80 0.58 – 1.12	0.194	0.388	0.64 0.41 – 1.00	0.045	0.135
t-tau	1.36 0.92 – 2.00	0.116	0.248	0.73 0.53 – 1.02	0.063	0.189	0.72 0.46 – 1.14	0.154	0.308
MTA	1.48 0.84 – 2.52	0.165	0.248	1.24 0.81 – 1.90	0.315	0.450	0.78 0.46 – 1.30	0.342	0.410
Vascular									
WMHs	0.78 0.48 – 1.24	0.314	0.314	1.03 0.68 – 1.54	0.896	0.896	0.71 0.38 – 1.27	0.260	0.390
Microbleeds	0.68 0.41 – 1.07	0.109	0.248	0.81 0.49 – 1.28	0.375	0.450	0.91 0.48 – 1.65	0.776	0.776

Note: In bold associations that are statistically significant. All analyses were adjusted for age, sex, and cohort.

Abbreviations: Aβ, Amyloid-beta; CN, cognitively normal; CI, confidence interval; FDR, false discovery rate; MCI, mild cognitive impairment; MTA, medial temporal atrophy as defined by Scheltens score; OR, odds ratio; p-tau, phosphorylated tau; t-tau, total tau; WMH, white matter hyperintensity as defined by Fazekas score.




FIGURE 1 Associations of DM with AD and vascular biomarkers. Shown are the ORs from the logistic regression analyses assessing the association of DM with AD biomarkers (abnormal A β , p-tau181, t-tau, or MTA) and vascular burden (WMH or microbleeds). All analyses were adjusted for age, sex, and cohort. A β , amyloid beta; AD, Alzheimer's disease; CN cognitively normal, DM, diabetes mellitus; MCI, mild cognitive impairment; MTA, medial temporal hypertrophy; OR, odds ratio; p-tau, phosphorylated tau; t-tau, total tau; WMH, white matter hyperintensity. ** $p < 0.01$, * $p < 0.05$. Unadjusted for multiple comparisons.

After adjusting for APOE $\epsilon 4$ carriership and cardiometabolic comorbidities (obesity, hypertension, and hypercholesterolemia), or FDR correction for multiple comparisons, only the association between DM and lower odds of abnormal A β in the dementia group remained significant. Results of the adjusted models are shown in Table 2 (FDR correction) and Table S6 (adjusted models). Table S7 shows ORs of all covariates included in the last model.

3.3 | Associations of DM with profiles of A β in combination with tau, MTA, and vascular burden markers

Secondary analyses assessed associations of DM with different profiles of A β in combination with one other biomarker being p-tau181, t-tau, MTA, WMHs, or microbleeds, as shown in Table 3. Of interest, in CN individuals with normal A β , DM was associated with higher odds of abnormal t-tau (OR = 1.57, 95% CI: 1.00–2.47, $p = 0.048$) or MTA (OR = 1.96, 95% CI: 1.05–3.68, $p = 0.04$), as compared to individuals with normal levels of both A β and the other biomarker. These associations were not found in CN individuals with abnormal A β . No associations of DM with profiles of A β in combination with p-tau181, WMHs, or microbleeds were found.

In MCI, DM was associated with a lower odds of having abnormal A β and p-tau181 (OR = 0.60, 95% CI: 0.39–0.91, $p = 0.02$) or abnormal A β and t-tau (OR = 0.56, 95% CI: 0.37–0.84, $p = 0.01$) as compared to persons with normal levels of both A β and p-tau181/t-tau. DM was also not associated with having only abnormal A β , p-tau181, or t-tau. We did not find associations of DM with profiles of A β in combination with MTA, WMHs, or microbleeds.

In individuals with dementia, DM was associated with a lower odds of having abnormal A β regardless of p-tau181, t-tau, or WMH status,

as compared to persons with both normal A β and normal p-tau181/t-tau/WMHs (see Table 3; A+ p-tau+ vs A- p-tau-: OR = 0.29, $p < 0.001$, A+ p-tau- vs A- p-tau-: OR = 0.38, $p = 0.01$, A+ t-tau+ vs A- t-tau-: OR = 0.32, $p = 0.003$, A+ t-tau- vs A- t-tau-: OR = 0.37, $p = 0.02$, A+ WMH+ vs A- WMH-: OR = 0.32, $p = 0.02$, and A+ WMH- vs A- WMH-: OR = 0.44, $p = 0.048$). Most associations were attenuated after adjustment or FDR correction for multiple comparisons, as presented in Table 3.

Other significant differences between the profile groups are listed in Table S8. Generally, these associations similarly showed that DM was associated with a lower odds of having abnormal A β as compared to groups with normal A β . In addition, in CN individuals, DM was associated with a higher odds of only abnormal p-tau181, t-tau, or MTA, as compared to only abnormal A β .

3.4 | Sensitivity analyses

When the main analyses in cohorts using only CSF measures of A β were repeated (i.e., excluding 342 individuals with PET measures), the association between DM and A β remained similar in the MCI group (OR = 0.66, 95% CI: 0.48–0.91, $p = 0.011$) and dementia group (OR = 0.41, 95% CI: 0.24–0.71, $p = 0.001$).

We additionally explored whether DM medication use (i.e., insulin or oral glucose-lowering drugs) changed the association of DM with AD biomarkers and vascular burden. Results did not differ between individuals using DM medication ($n = 441$) as compared to those not using DM medication ($n = 85$).

Logistic regression analyses including interactions with each cohort showed variability across cohorts in the strength of the identified associations of DM with AD biomarkers and vascular burden. The comparison of odds of individuals with versus without DM between cohorts is shown in Figure S2.

TABLE 3 Associations of DM with different profiles of AD and vascular biomarkers.

	N	CN		N	MCI		N	Dementia	
		OR (CI)	p		OR (CI)	p		OR (CI)	p
A- p-tau- vs	1508	1.27	0.292	441	1.12	0.636	51	0.56	0.269
A- p-tau+	295	0.82 – 1.96	0.106	177	0.69 – 1.82	0.381	44	0.20 – 1.56	0.011^{b,c}
A+ p-tau-	480	0.70	0.911	357	0.82	0.016^b	211	0.38	<0.001^{a,b,c}
A+ p-tau+	195	0.45 – 1.08		480	0.53 – 1.27		962	0.18 – 0.80	
		1.03			0.60			0.29	
		0.59 – 1.82			0.39 – 0.91			0.14 – 0.58	
A- t-tau- vs	1,567	1.57	0.048^c	444	0.88	0.614	46	0.70	0.486
A- t-tau+	237	1.00 – 2.47	0.292	174	0.53 – 1.45	0.180	49	0.26 – 1.89	0.022^{b,c}
A+ t-tau-	499	0.80	0.744	330	0.74	0.006^{a,b}	191	0.37	0.003^{a,b,c}
A+ t-tau+	166	0.52 – 1.21		506	0.48 – 1.15		980	0.16 – 0.87	
		0.90			0.56			0.32	
		0.48 – 1.70			0.37 – 0.84			0.15 – 0.67	
A- MTA- vs	1,584	1.96	0.035^c	400	1.29	0.391	28	1.02	0.980
A- MTA+	161	1.05 – 3.68	0.784	116	0.72 – 2.32	0.089	29	0.19 – 5.59	0.734
A+ MTA-	547	0.95	0.687	415	0.68	0.504	433	0.80	0.451
A+ MTA+	97	0.65 – 1.39		183	0.44 – 1.06		373	0.22 – 2.94	
		0.83			0.82			0.60	
		0.34 – 2.02			0.46 – 1.46			0.16 – 2.26	
A- WMH- vs	1,527	0.65	0.155	405	1.35	0.295	50	0.68	0.646
A- WMH+	246	0.35 – 1.18	0.175	124	0.77 – 2.36	0.489	17	0.13 – 3.51	0.048
A+ WMH-	513	0.76	0.667	441	0.86	0.194	621	0.44	0.018^b
A+ WMH+	135	0.50 – 1.13		194	0.56 – 1.32		209	0.19 – 0.99	
		0.86			0.68			0.32	
		0.44 – 1.70			0.38 – 1.22			0.12 – 0.82	
A- V ^{MB} - vs	1,341	0.59	0.084	426	0.69	0.312	47	0.66	0.724
A- MB+	242	0.32 – 1.07	0.430	82	0.33 – 1.43	0.063	11	0.07 – 6.45	0.262
A+ MB-	495	0.85	0.480	443	0.67	0.167	605	0.59	0.279
A+ MB+	119	0.57 – 1.27		143	0.45 – 1.02		171	0.23 – 1.49	
		0.77			0.65			0.56	
		0.37 – 1.59			0.35 – 1.20			0.20 – 1.60	

Note: Persons without any AD or vascular burden biomarkers present were used as reference group. + indicates abnormality of markers, whereas - indicates normal biomarkers. All analyses were adjusted for age, sex, and cohort. Bold text indicates associations that are statistically significant.

Abbreviations: A, amyloid; AD, Alzheimer's disease; APOE, apolipoprotein E; CN, cognitively normal; CI, confidence interval; FDR, false discovery rate; MB, microbleed; MCI, mild cognitive impairment; MTA, medial temporal atrophy; OR, odds ratio; p-tau, phosphorylated tau; t-tau, total tau; WMH, white matter hyperintensity.

^aRemains significant after FDR correction.

^bRemains significant after adjustment for APOE ε4 carriership.

^cRemains significant after adjustment for cardiometabolic comorbidities (obesity, hypertension, and hypercholesterolemia).

4 | DISCUSSION

In this study, we demonstrated that DM status is associated with a lower odds of Aβ and p-tau181 abnormality in individuals with dementia, and, to a lesser extent, with a lower odds of Aβ abnormality in MCI. Moreover, in CN individuals with normal levels of Aβ, DM was associated with a higher odds of neurodegeneration (abnormal t-tau and MTA). DM was not associated with MRI markers of vascular burden. These results suggest that DM is not associated with Aβ pathology but may be associated with other neurodegenerative pathways involving t-tau and MTA.

We found that DM was consistently associated with a lower odds of Aβ abnormality in individuals with dementia, independent from other AD and vascular biomarkers. This finding is in line with our recent meta-analysis demonstrating an association of DM and impaired glu-

cose metabolism with decreased Aβ pathology.³⁷ This reversed association was observed only for memory clinic studies, and more strongly in study samples with a higher prevalence of dementia and lower cognition scores. This reversed association could be explained by an association of DM with non-AD dementia but not AD dementia. What seems an inverse association might reflect persons in the dementia group with other diabetes-related or vascular pathologies rather than Aβ. The fact that we did not find associations of DM with vascular pathologies might be explained by co-occurring vascular burden patterns in persons with DM and persons without DM but abnormal amyloid. Recent cohort and polygenic risk score studies similarly suggest that type 2 DM is not associated with AD dementia but rather with other types of dementia such as vascular dementia.^{38,39} Another systematic reviews similarly indicates that DM is not associated with post-mortem AD pathology.⁴⁰ It is important to note is that even

though DM might not be linked to AD, it might influence the cumulative clinical progression to (AD) dementia.

Moreover, we found that DM status was associated with markers of neurodegeneration, t-tau and MTA, but only in CN individuals with normal A β biomarkers. The subtle association between DM and neurodegeneration was diluted in clinical populations. To our knowledge, this is the first study to emphasize that neurodegeneration in DM takes place at a relatively early stage and is not induced through pathways involving A β pathology. This is in line with our previous work, where we found associations between DM and tau (CSF p-tau, t-tau, and PET temporal tau) but not A β pathology.^{37,41} Associations with p-tau and t-tau were more often found in population studies as compared to memory clinic studies, corresponding to our current findings for individuals with normal cognition. These findings underscore the importance of assessing associations in different settings and across different ages. Longitudinal studies might help exploring trajectories of vascular versus AD biomarker changes. Similarly, vascular risk in general, as measured by the Framingham general cardiovascular risk score, has been shown previously to be associated with p-tau and t-tau but not A β pathology.⁴² Although similar patterns of brain insulin resistance are observed in DM and AD,^{5,7} it has been suggested that insulin resistance in AD drives neurodegeneration through pathways other than A β pathology.⁴³ Different pathways could involve inflammation, brain glucose metabolism, brain insulin resistance, oxidative stress, or mitochondrial dysfunction.⁴⁴

Although clear associations have been shown in previous studies,^{6,11,12} we did not observe associations of DM with vascular burden and only found associations with neurodegeneration for A β -normal individuals. This could be explained by the lower prevalence of DM and vascular disease in our study sample, as mostly memory clinic populations with a focus on AD were included. The dementia group most likely included a high frequency of AD patients, possibly inducing selection bias regarding vascular contributions. In ADC, the largest cohort in our study, similar results were found.⁴⁵ Generally, studies have predominantly indicated clear associations of type 2 DM with lacunae and infarcts,⁶ which were not measured in our study. In addition, previous studies typically involved healthy mid-life participants, whereas our study participants were on average older and mostly included clinical populations. This underscores the importance of exploring differences across settings and age.

The role of DM medication use should be further explored in future studies. Assessing the effects of DM medication use is usually complicated by the fact that almost all individuals diagnosed with DM use medication. Earlier studies have shown, however, that insulin or metformin use may slow the progression to AD dementia,^{46,47} and that only untreated DM is associated with increased A β pathology.⁴⁸

4.1 | Strengths and limitations

Through the unique collaboration between multiple memory clinic and aging cohorts we were able to assess the association of DM with AD biomarkers and vascular burden on a large scale and across differ-

ent cognitive groups. Although data pooling brings many advantages such as larger sample sizes and power, it also comes with limitations. We could not consider type of dementia, as not all cohorts provided this information. We assume, however, that most individuals were diagnosed with AD, as most cohorts focused on the AD continuum and this is the most common type of dementia. For the same reason, DM type, duration, and severity could not be considered. In addition, the A β 42/40 ratio might have slightly lower diagnostic accuracy than A β 42 alone. Another limitation is that not all cohorts used the same inclusion criteria, definitions for cognitive status and DM, and biomarker measurement methods (as shown in Tables S1 and S3), which could explain differences in associations between the cohorts as shown in the sensitivity analysis. However, our analyses partly corrected for this by including demographics and cohort as covariates. Although sample sizes differed across the different sub-analyses due to differences in data availability per cohort, the results of this study remained mostly consistent throughout our secondary analyses. Associations of DM with non-AD neurodegeneration and vascular burden markers may be underestimated. Vascular contributions may be relatively low, as our study sample focused largely on individuals within the AD continuum. The prevalence of DM was relatively low as compared to the general elderly population in Europe, estimated at above 15% in persons 50 years of age or older.⁴⁹ In addition, we used only MRI visual rating scales. Although these are used in routine clinical practice, visual rating scales may be less sensitive as compared to volumetric MRI measures. In addition, localization of vascular burden, especially microbleeds, would provide much more information. Vascular measures such as lacunae and infarcts would probably also help capturing vascular consequences of DM.

5 | CONCLUSIONS AND FUTURE DIRECTIONS

Our study showed that DM is consistently associated with lower odds of A β in individuals with dementia, whereas DM was associated with neurodegeneration markers of t-tau and MTA in CN individuals with normal A β . These findings suggest that DM may be associated with cognitive decline through processes of neurodegeneration different from A β pathways. This supports the hypothesis that DM is associated mainly with causes of dementia other than AD. This knowledge is particularly relevant for improving diagnostic procedures as well as prevention strategies in the future.

Future studies should explore associations of metabolic markers (i.e., plasma glucose, hemoglobin A1c [HbA1c], and insulin resistance) with DM, as well as possible mediating effects of vascular risk factors (such as body mass index, blood pressure, and cholesterol level) on the association between DM and neurodegenerative markers. This could provide relevant insights in the mechanisms underlying the association between DM and dementia. As heterogeneous results are found across studies, future studies should explore possible differences between populations (e.g., diagnostic groups, age groups, but also multi-ethnic and variable socioeconomic populations) and changes of biomarkers

and vascular burden over time. Moreover, future prognostic procedures could be improved through examining whether DM and AD biomarkers contribute independently or synergistically to cognitive decline and dementia.

AFFILIATIONS

¹Alzheimer Center Limburg, Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, Netherlands

²Alzheimer Center and Department of Neurology, Amsterdam Neuroscience Campus, VU University Medical Center, Amsterdam, Netherlands

³Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

⁴Fundación CITA-Alzhéimer Fundazioa, Donostia, Gipuzkoa, Spain

⁵Charles University, 2nd Faculty of Medicine, Motol University Hospital, Prague, Czech Republic

⁶CHUV Lausanne Hospital, Lausanne, Switzerland

⁷Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

⁸Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium

⁹Department of Neurology, Universitair Ziekenhuis Brussel and NEUR Research Group, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium

¹⁰Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland

¹¹Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich and University of Zürich, Zürich, Switzerland

¹²Sant Pau Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

¹³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain

¹⁴Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

¹⁵1st Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece

¹⁶Neurochemistry Lab, Department of Laboratory Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

¹⁷Neurology, University Hospitals Leuven, Leuven, Belgium

¹⁸Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium

¹⁹Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden

²⁰Department of Geriatric Psychiatry, Zentralinstitut Für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany

²¹Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

²²Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK

²³UK Dementia Research Institute at UCL, London, UK

²⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

²⁵Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium

²⁶Translational Medicine Neuroscience, UCB Biopharma SPRL, Braine-l'Alleud, Belgium

²⁷Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK

²⁸Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

²⁹Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands

³⁰Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

³¹Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

³²Department of Biochemistry and Biotechnology, Rovira i Virgili University (URV), Reus, Spain

³³Institute of Health Pere Virgili (IISPV), Avinguda del Doctor Josep Laporte, Tarragona, Spain

³⁴Center of Environmental, Food and Toxicological Technology - TecnATox, Rovira i Virgili University, Tarragona, Spain

³⁵Clinical Psychology Department, University Hospital of Bellvitge, Barcelona, Spain

³⁶Psychoneurobiology of Eating and Addictive Behaviors Group, Neurosciences Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

³⁷CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain

³⁸Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

³⁹Unitat de Nutrició Humana, ANUT-DSM group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili Sant Llorenç 21, Reus, Spain

⁴⁰National Centre for Register-based Research, Department of Economics and Business, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark

⁴¹The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark

ACKNOWLEDGMENTS

The authors are grateful to all cohorts that contributed to this study by sharing their data with us: Amsterdam Dementia Cohort (ADC; involving W.V.D.F., J.M., and A.V.H.), BioBank Alzheimer Center Limburg (BB-ACL; involving I.R.), EMIF Preclin-AD and EMIF 90+ (involving N.L. and A.D.B.), Czech Brain Aging Study (CBAS; involving J.H. and K.V.), Gipuzkoa Alzheimer Project (GAP; involving P.M.L.), CLEMENS (involving O.R. and D.D.), and Metabolic Syndrome in Men (MET-SIM; involving M.L. and A.H.). In addition, data used in preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: http://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. Data also involved consortium data from European Medical Information Framework (EMIF) Multimodal Biomarker Discovery Study (MBD) (involving S.E., J.P., A.L., A.W., M.T., C.E.T., R.V.,

Y.F.L., L.F., H.Z., J.S., and S.L.). We would also like to thank the H2020 PRIME consortium (involving V.V.G., W.J.J., J.B., G.F., B.F., G.P., M.B., S.J.M., F.F.A., J.S.S., S.D., P.J.V., and S.B.), especially work package 1, for their valuable support and contributions. This research was supported by funding from the European Community's Horizon H2020/2014 - 2020 under grant agreement no. 847879 (PRIME). The content of the paper is solely the responsibility of the authors and does not necessarily represent the official views of the European Commission. This work used data and/or samples from the EPAD project, which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement no. 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network, grant agreement no. 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no. 831434) EPND (IMI 2 Joint Undertaking (JU), grant no. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer's Drug Discovery Foundation, Alzheimer's Association, Health Holland, the Dutch Research Council (ZonMw), The Selfridges Group Foundation, and Alzheimer Netherlands. C.E.T. is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health-Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.E.T. is recipient of TAP-dementia, a ZonMW-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer's Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). M.B. received the ICREA Academy 2023 Distinction from the Autonomous Government of Catalonia.

CONFLICT OF INTEREST STATEMENT

G.P. is director and chief scientific officer of Drug Target ID, Ltd., but activities at this company do not constitute competing interests regarding this paper. C.E.T. has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly,

Fujirebio, Instant Nano Biosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, and Vivoryon. She is Editor-in-Chief of *Alzheimer's Research & Therapy*, and serves on editorial boards of *Medi-dact Neurologie/Springer*, and *Neurology: Neuroimmunology & Neuroinflammation*. She had consultancy/speaker contracts with Eli Lilly, Merck, Novo Nordisk, Olink, and Roche. B.F. has received educational speaking fees and travel support from Medice. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alec-tor, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothema, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). S.L. currently works at Johnson & Johnson. F.F.A. and S.J.M. have been consultants/speakers for NovoNordisk. P.J.V. received grants from Innovative Medicine Initiative, ZonMw, and Biogen. All other authors have nothing to disclose. Author disclosures are available in the [Supporting Information](#).

CONSENT STATEMENT

All participants provided written informed consent at their respective study sites.

ORCID

Veerle van Gils  <https://orcid.org/0000-0001-8240-5367>

REFERENCES

1. Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. *Neurología (English Edition)*. 2017;32(8):523-532.
2. Fanelli G, Mota NR, Salas-Salvadó J, et al. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review. *Neurosci Biobehav Rev*. 2022;143:104927.
3. Gómez-Martínez C, Babio N, Júlvez J, et al. Glycemic dysregulations are associated with worsening cognitive function in older participants at high risk of cardiovascular disease: two-year follow-up in the PREDIMED-Plus study. *Front Endocrinol (Lausanne)*. 2021;12:754347.
4. Zhang J, Chen C, Hua S, et al. An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer's disease. *Diabetes Res Clin Pract*. 2017;124:41-47.
5. Shieh JC-C, Huang P-T, Lin Y-F. Alzheimer's disease and diabetes: insulin signaling as the bridge linking two pathologies. *Mol Neurobiol*. 2020;57:1966-1977.
6. Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. *The Lancet Neurol*. 2020;19(8):699-710.
7. Fanelli G, Franke B, Fabbri C, et al. Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions. *medRxiv*. 2024.
8. Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia*. 2018;14(4):535-562.

9. Lu Y, Jiang X, Liu S, Li M. Changes in cerebrospinal fluid tau and β -amyloid levels in diabetic and prediabetic patients: a meta-analysis. *Front Aging Neurosci.* 2018;10:271.
10. Piri R, Naghavi-Behzad M, Gerke O, Høilund-Carlsen PF, Vafaei MS. Investigations of possible links between Alzheimer's disease and type 2 diabetes mellitus by positron emission tomography: a systematic review. *Clinical and Translational Imaging.* 2019;7:327-336.
11. Zhang T, Shaw M, Cherbuin N. Association between type 2 diabetes mellitus and brain atrophy: a meta-analysis. *Diabetes & Metabolism J.* 2022;46(5):781-802.
12. Ma T, Li Z-Y, Yu Y, et al. Gray and white matter abnormality in patients with T2DM-related cognitive dysfunction: a systemic review and meta-analysis. *Nutrition & Diabetes.* 2022;12(1):39.
13. van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. *J Alzheimers Dis.* 2018;62(3):1091-1111.
14. van Gils V, Ramakers I, Jansen WJ, et al. Contributions of vascular burden and amyloid abnormality to cognitive decline in memory clinic patients. *J Alzheimer's Dis Rep.* 2023;7(1):1299-1311.
15. Konijnenberg E, Carter SF, Ten Kate M, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. *Alzheimers Res Ther.* 2018;10(1):75.
16. Legdeur N, Badissi M, Carter SF, et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. *BMC Geriatr.* 2018;18(1):289.
17. Sheardova K, Vyhnaek M, Nedelska Z, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. *BMJ Open.* 2019;9(12):e030379.
18. Ecay-Torres M, Estanga A, Tainta M, et al. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. *Neurology.* 2018;91(3):e217-e26.
19. Draganski B, Kherif F, Damian D, Demonet JF. A nation-wide initiative for brain imaging and clinical phenotype data federation in Swiss university memory centres. *Curr Opin Neurol.* 2019;32(4):557-563.
20. Westwood S, Liu B, Baird AL, et al. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. *Alzheimers Res Ther.* 2017;9(1):31.
21. Bos I, Vos S, Vandenberghe R, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. *Alzheimers Res Ther.* 2018;10(1):64.
22. Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW. European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. *BMJ Open.* 2019;8(12):e021017.
23. Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. *BMJ.* 2018;362:k1497.
24. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.* 2004;256(3):183-194.
25. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. *J Intern Med.* 2004;256(3):240-246.
26. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia.* 2011;7(3):270-279.
27. Morris JC. The Clinical Dementia Rating (CDR). *Neurology.* 1993;43(11):2412-a.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of health and human services task force on Alzheimer's disease. *Neurology.* 1984;34(7):939-944.
29. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. *Eur J Neurol.* 2012;19(9):1159-1179.
30. Jansen WJ, Janssen O, Tijms BM, et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. *JAMA Neurol.* 2022;79(3):228-243.
31. Tijms BM, Willems EAJ, Zwan MD, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid- β 1-42 analysis results. *Clin Chem.* 2018;64(3):576-585.
32. Ingala S, De Boer C, Masselink LA, et al. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. *Alzheimer's & Dementia.* 2021;17(7):1189-1204.
33. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry.* 1992;55(10):967-972.
34. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *Am J Neuroradiol.* 1987;8(3):421-426.
35. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. *Neurology.* 2004;63(1):94-100.
36. Fazekas F, Barkhof F, Wahlund L, et al. CT and MRI rating of white matter lesions. *Cerebrovasc Dis.* 2002;13(Suppl. 2):31-36.
37. van Gils V, Rizzo M, Côte J, et al. The association of glucose metabolism measures and diabetes status with Alzheimer's disease biomarkers of amyloid and tau: a systematic review and meta-analysis. *Neuroscience & Biobehavioral Reviews.* 2024;159:105604.
38. Celis-Morales CA, Franzén S, Eeg-Olofsson K, et al. Type 2 diabetes, glycemic control, and their association with dementia and its major subtypes: findings from the Swedish National Diabetes Register. *Diabetes Care.* 2022;45(3):634-641.
39. Dybjer E, Kumar A, Nägga K, et al. Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study. *Brain Commun.* 2023;5(2):fcad054.
40. Hadley G, Zhang J, Harris-Skillman E, Alexopoulou Z, DeLuca GC, Pendlebury ST. Cognitive decline and diabetes: a systematic review of the neuropathological correlates accounting for cognition at death. *Journal of Neurology, Neurosurgery & Psychiatry.* 2022;93(3):246-253.
41. van Gils V, Tao Q, Ang TF, et al. Associations between glucose metabolism measures and amyloid- β and tau load on PET 14 years later: findings from the Framingham Heart Study. *Diabetes Care.* 2024;47(10):1787-1793.
42. Yu GX, Ou YN, Bi YL, et al. Tau Pathologies Mediate the Associations of vascular risk burden with cognitive impairments in non-demented elders: the CABLE study. *The Journal of Prevention of Alzheimer's Disease.* 2022;9(1):136-143.
43. Lane EM, Hohman TJ, Jefferson AL. Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers. *Brain Imaging Behav.* 2017;11(6):1779-1786.
44. Verdile G, Keane KN, Cruzat VF, et al. Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. *Mediators Inflamm.* 2015;2015:105828.
45. Exalto LG, van der Flier WM, Scheltens P, Vrenken H, Biessels GJ. Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. *J Diabetes Complications.* 2014;28(1):85-90.
46. Kellar D, Lockhart SN, Aisen P, et al. Intranasal Insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and Alzheimer's disease. *J Prev Alzheimers Dis.* 2021;8(3):240-248.
47. Ning P, Luo A, Mu X, Xu Y, Li T. Exploring the dual character of metformin in Alzheimer's disease. *Neuropharmacology.* 2022;207:108966.
48. McIntosh EC, Nation DA, Initiative AsDN. Importance of treatment status in links between type 2 diabetes and Alzheimer's disease. *Diabetes Care.* 2019;42(5):972-979.

49. Rooney MR, Fang M, Ogurtsova K, et al. Global prevalence of prediabetes. *Diabetes Care*. 2023;46(7):1388-1394.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: van Gils V, Jansen WJ, van der Flier WM, et al. The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts. *Alzheimer's Dement*. 2025;21:e70804. <https://doi.org/10.1002/alz.70804>